ClinicalTrials.gg
Drug

Zanidatamab clinical trials

Also written ZW25, ZIIHERA® and JZP598.

studies test it
31
open now
22
in phase 3
6
first study started
2010

How each study uses zanidatamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the zanidatamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
20 Nov 2024 · ZIIHERA · BLA 761416 (FDA, Drugs@FDA)
European Union
27 Jun 2025 · Ziihera · EMEA/H/C/006380 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Zanidatamab
22
ZW25 (Zanidatamab)
4
Zanidatamab Combined with Chemotherapy
2

Brand

ZIIHERA®
9

Development codes

ZW25
10
JZP598
6

Studies by the year they started

29 studies that test it; most in 2026 (9); 2 more planned to start later

Studies that test zanidatamab, by start year
YearStudies
20101
20161
20192
20203
20213
20221
20231
20244
20254
20269

By phase

A phase 1/2 study counts in both.

Phase 1
5
Phase 2
23
Phase 3
6

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 20

Jazz Pharmaceuticals (10) · UNICANCER (3) · M.D. Anderson Cancer Center (2) · QuantumLeap Healthcare Collaborative (2) · BeOne Medicines (1) · Memorial Sloan Kettering Cancer Center (1) · Anhui Provincial Hospital (1) · Zhifeng Zhao, PhD (1)

Often tested with

Tested in the same studies.

Tislelizumab (4) · ALX148 (2) · Futibatinib (2) · Ivosidenib (2) · Trastuzumab (2) · Neratinib (2) · Niraparib (2) · Cisplatin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test zanidatamab, phase 3 first.

Studies

Open first, then newest update. How each study uses zanidatamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 31

See all 31 studies that test zanidatamab →

Given beside what is tested · 3 — zanidatamab is usual care or a partner of the new treatment

Codes

What other systems call zanidatamab · ClinicalTrials.gg INT002015

  • MeSH (NLM) C000726995zanidatamabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Z20OC92TDIZANIDATAMABConfirmed FDA, NLM
  • NCI Thesaurus C130010ZanidatamabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.